Biotechnology firm Akeso, Inc. (9926.HK) released updated findings from a prospective Phase II clinical trial on November 6, 2026, evaluating its first-in-class bispecific antibody ivonescimab (AK112) in resectable non-small cell lung cancer (NSCLC). In clinical cohorts administered neoadjuvant ivonescimab in combination with platinum-based doublet chemotherapy, the study demonstrated an objective pathological complete response (pCR) rate of 50.7 percent alongside a major pathological response (MPR) rate of 72.4 percent. The clinical outcomes establish a benchmark for perioperative immunotherapy in early-stage solid tumors, validating dual blockade of programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF) before curative surgical intervention.
Phase II Clinical Trial Endpoints and Pathological Outcomes for Ivonescimab
- Major Pathological Response (MPR Criteria): 72.4% (Residual Viable Neoplasm Not Exceeding 10%)
Dual Mechanistic Synergy Eradicates Solid Neoplasms Prior to Surgical Resection
Treating locally advanced Stage II and Stage III non-small cell lung cancer presents complex clinical challenges due to microscopic systemic micrometastases.
Even following curative pulmonary lobectomies, five-year systemic recurrence rates remain elevated among patient populations. While standard neoadjuvant regimens coupling single-target PD-1 monoclonal antibodies with chemotherapy achieved pCR rates between twenty and twenty-five percent, over three-quarters of excised pathology specimens retain viable invasive malignant cells. Ivonescimab pairs PD-1 immune checkpoint inhibition with local anti-angiogenic VEGF blockade within a single engineered molecule. Blocking VEGF normalizes aberrant vascular permeability and reduces interstitial fluid pressure within the tumor core, facilitating increased infiltration of cytotoxic CD8-positive T lymphocytes and chemotherapeutic molecules directly into dense malignant beds, eradicating tumor cells before surgical intervention.
High R0 Resection Success Affirms Safety Across Thoracic Surgical Procedures
Thoracic surgical investigators emphasized that preoperative immunotherapy must not compromise pulmonary microvascular elasticity or elevate intraoperative surgical mortality.
Prior investigations evaluating systemic anti-VEGF monoclonal antibodies encountered surgical hesitance due to concerns regarding impaired vascular wound healing, bronchial dehiscence, and severe thoracic hemorrhage. Within the ivonescimab Phase II trial, patients completed three to four cycles of neoadjuvant therapy, achieving an R0 resection success rate of 94.6 percent without statistically significant variance in intraoperative complications compared to chemotherapy alone. Grade 3 or higher treatment-related adverse reactions occurred in 24.1 percent of patients, predominantly transient hematologic toxicities. Resected histological specimens confirmed complete fibrous substitution and dense lymphocytic infiltration, validating clinical tumor regression.
Strategic Paradigm Shift from Metastatic Salvage to Early-Stage Curative Oncology
The clinical data presented by Akeso sparked commercial re-evaluation across international biotechnology markets and oncology congresses.
Oncology research strategists observe that following ivonescimab's demonstrated survival benefits in direct head-to-head clinical trials against pembrolizumab in metastatic disease, achieving substantial pathological response rates in resectable settings confirms the therapeutic utility of bispecific antibodies across curative treatment windows. Akeso confirmed that registrational Phase III global clinical protocols evaluating event-free survival (EFS) and overall survival (OS) are finalized, with multi-regional clinical trial site screening initiating across North America, Europe, and Asia. Replicating these response rates in Phase III trials could position bispecific checkpoint-angiogenesis inhibitors as the clinical standard of care for perioperative thoracic oncology. Clinical research directors conclude that integrating targeted anti-angiogenic activity with immune checkpoint blockade provides a transformative blueprint for early-stage oncology trials, accelerating curative therapeutic strategies across diverse tumor types worldwide.
